With Rezdiffra’s approval, GLPs moving into the space, and the wave of promising therapeutics in phrase I-III trials, MASH therapeutics have seen an unprecedented boom in recent months.

Don’t miss the 8th MASH Drug Development Summit’s industry-specific curated agenda spanning preclinical, translational, clinical and regulatory MASH developments designed to help you to overcome barriers in the development and commercialization of MASH therapies.

What are the top program features to look forward to in 2024?

• Delve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with BMS, Pfizer and AstraZeneca
• Accelerate your clinical trial design by optimizing cirrhosis, MASH and fibrosis targets in trials with AstraZeneca and 89Bio
• Examine how GLP-1s can be leveraged in MASH to combat the disease drivers with Altimmune and Seal Rock Therapeutics
• Explore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca
• Leverage AI techniques and real-world evidence to integrate data, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca

Find out more here.

This is a conversation you won’t want to miss! Discover pricing and registation information here to discover how you can harness competitive intelligence from 3 days of cutting-edge content to supercharge your MASH therapeutic pipeline.